Nothing Special   »   [go: up one dir, main page]

MA26653A1 - Pyrrolo [2,3- d] pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant - Google Patents

Pyrrolo [2,3- d] pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant

Info

Publication number
MA26653A1
MA26653A1 MA25629A MA25629A MA26653A1 MA 26653 A1 MA26653 A1 MA 26653A1 MA 25629 A MA25629 A MA 25629A MA 25629 A MA25629 A MA 25629A MA 26653 A1 MA26653 A1 MA 26653A1
Authority
MA
Morocco
Prior art keywords
pyrimidines
preparation
pharmaceutical compositions
compositions containing
new pyrrolo
Prior art date
Application number
MA25629A
Other languages
English (en)
Inventor
Andrew Blumenkopf Todd
Frank Brown Matthew
Steven Changelian Paul
Edward Flanagan Mark
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26653A1 publication Critical patent/MA26653A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA25629A 1998-06-19 1999-06-16 Pyrrolo [2,3- d] pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant MA26653A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8988698P 1998-06-19 1998-06-19

Publications (1)

Publication Number Publication Date
MA26653A1 true MA26653A1 (fr) 2004-12-20

Family

ID=22220084

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25629A MA26653A1 (fr) 1998-06-19 1999-06-16 Pyrrolo [2,3- d] pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant

Country Status (47)

Country Link
US (2) US6635762B1 (fr)
EP (1) EP1087971B1 (fr)
JP (1) JP3497823B2 (fr)
KR (1) KR100452054B1 (fr)
CN (1) CN1125070C (fr)
AP (1) AP1157A (fr)
AR (1) AR016498A1 (fr)
AT (1) ATE270673T1 (fr)
AU (1) AU758427B2 (fr)
BG (1) BG65063B1 (fr)
BR (1) BR9912171A (fr)
CA (1) CA2335186C (fr)
CO (1) CO5320601A1 (fr)
CZ (1) CZ20004726A3 (fr)
DE (1) DE69918552T2 (fr)
DK (1) DK1087971T3 (fr)
EA (2) EA006034B1 (fr)
EG (1) EG23758A (fr)
ES (1) ES2223172T3 (fr)
GE (1) GEP20084336B (fr)
GT (1) GT199900091A (fr)
HK (1) HK1036800A1 (fr)
HN (1) HN1999000083A (fr)
HR (1) HRP20000886B1 (fr)
HU (1) HUP0103472A3 (fr)
ID (1) ID27595A (fr)
IL (2) IL139598A0 (fr)
IS (2) IS2395B (fr)
MA (1) MA26653A1 (fr)
MY (1) MY125802A (fr)
NO (2) NO318786B1 (fr)
NZ (1) NZ508034A (fr)
OA (1) OA11571A (fr)
PA (1) PA8474101A1 (fr)
PE (1) PE20000639A1 (fr)
PL (1) PL198639B1 (fr)
PT (1) PT1087971E (fr)
SA (1) SA99200285B1 (fr)
SI (1) SI1087971T1 (fr)
SK (1) SK286685B6 (fr)
TN (1) TNSN99125A1 (fr)
TR (1) TR200003720T2 (fr)
TW (1) TW542834B (fr)
UA (1) UA63013C2 (fr)
WO (1) WO1999065909A1 (fr)
YU (1) YU79700A (fr)
ZA (1) ZA994003B (fr)

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
EP1065207A1 (fr) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Dérivées de la naphthyridine, procédés pour leur preparation, leur utilisation, et compositions pharmaceutique les contenant
WO2001025220A1 (fr) * 1999-10-07 2001-04-12 Amgen Inc. Inhibiteurs de triazine kinase
DE19948417A1 (de) * 1999-10-07 2001-04-19 Morphochem Ag Imidazol-Derivate und ihre Verwendung als Arzneimittel
SK287188B6 (sk) 1999-12-10 2010-02-08 Pfizer Products Inc. Pyrolo [2,3-d]pyrimidínová zlúčenina, jej použitie a farmaceutická kompozícia alebo kombinácia s jej obsahom
EP1782800B1 (fr) * 2000-01-24 2013-12-18 Genzyme Corporation Procédés de détection d'inhibiteurs de JAK3
ATE369844T1 (de) * 2000-01-24 2007-09-15 Genzyme Corp Inhibitoren des jak/stat-weges und deren verwendung zur behandlung von allgemeiner primärer osteoarthritis
MY145722A (en) * 2000-04-27 2012-03-30 Abbott Lab Diazabicyclic central nervous system active agents
PT1294724E (pt) * 2000-06-26 2006-07-31 Pfizer Prod Inc Compostos pirrolo (2,3-d ) pirimidina como agentes imunosupressivos
US6864255B2 (en) 2001-04-11 2005-03-08 Amgen Inc. Substituted triazinyl amide derivatives and methods of use
US6881737B2 (en) 2001-04-11 2005-04-19 Amgen Inc. Substituted triazinyl acrylamide derivatives and methods of use
US7301023B2 (en) * 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
GB0115393D0 (en) * 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
MXPA03011998A (es) * 2001-06-23 2005-07-01 Aventis Pharma Inc Pirrolopirimidinas como inhibidores de protein cinasa.
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
US7323469B2 (en) 2001-08-07 2008-01-29 Novartis Ag 7H-pyrrolo[2,3-d]pyrimidine derivatives
GT200200234A (es) 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
US6642381B2 (en) 2001-12-27 2003-11-04 Hoffman-La Roche Inc. Pyrimido[5,4-e][1,2,4]triazine-5,7-diamine compounds as protein tyrosine phosphatase inhibitors
DE60305446D1 (de) 2002-01-07 2006-06-29 Eisai Co Ltd Desazapurine und deren verwendung
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
EP1388541A1 (fr) 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines utilisées comme inhibiteurs de kinases
AU2003276591A1 (en) 2002-11-26 2004-06-18 Pfizer Products Inc. Method of treatment of transplant rejection
US7253166B2 (en) * 2003-04-22 2007-08-07 Irm Llc 6-phenyl-7H-pyrrolo[2,3-d]pyrimidine compounds that induce neuronal differentiation in embryonic stem cells
WO2005044835A1 (fr) * 2003-10-27 2005-05-19 Genelabs Technologies, Inc. Procedes de preparation de derives 7-(2'-$g(b)-d-ribofuranosyl substitue)-4-(nr2r3)-5-(ethyn-1-yl substitue)-pyrrolo[2,3-d]pyrimidine
WO2005067546A2 (fr) * 2004-01-13 2005-07-28 Ambit Biosciences Corporation Derives et analogues de pyrrolopyrimidine et utilisation de ceux-ci dans le traitement a la prevention de maladies
GB0403606D0 (en) 2004-02-18 2004-03-24 Novartis Ag Organic compounds
CA2563699C (fr) * 2004-04-23 2014-03-25 Exelixis, Inc. Modulateurs de kinase et methode d'utilisation
EP1768662A2 (fr) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
EP1768982A2 (fr) 2004-06-29 2007-04-04 Amgen Inc. Pyrrolo[2, 3-d] pyrimidines qui modulent l'activite ack1 et lck
JP2008508358A (ja) 2004-08-02 2008-03-21 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド アリール−アミノ置換ピロロピリミジンマルチキナーゼ阻害化合物
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
FR2880626B1 (fr) * 2005-01-13 2008-04-18 Aventis Pharma Sa Derives de la purine, compositions les contenant et utilisation
WO2006091450A1 (fr) * 2005-02-18 2006-08-31 Lexicon Genetics Incorporated Composes 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine
CA2607299C (fr) 2005-05-13 2013-05-07 Irm, Llc Composes et compositions convenant comme inhibiteurs de proteine kinase
CN102127078A (zh) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
JP5071374B2 (ja) 2005-07-14 2012-11-14 アステラス製薬株式会社 ヘテロ環ヤヌスキナーゼ３阻害剤
EP1926735A1 (fr) 2005-09-22 2008-06-04 Incyte Corporation Inhibiteurs tetracycliques de janus kinases
NZ567133A (en) * 2005-09-30 2011-07-29 Vertex Pharma Deazapurines useful as inhibitors of janus kinases
AU2015201850B2 (en) * 2005-12-13 2017-03-02 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
BRPI0619817B8 (pt) 2005-12-13 2021-05-25 Incyte Corp composto 3-ciclopentil-3-[4-(7h-pirrol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]propanonitrila e sua composição
ATE531718T1 (de) * 2006-03-11 2011-11-15 Vernalis R&D Ltd Als hsp90-inhibitoren verwendete pyrrolopyrimidinderivate
EP2001884A1 (fr) * 2006-04-05 2008-12-17 Vertex Pharmaceuticals, Inc. Désazapurines utiles comme inhibiteurs des kinases janus
GB0608176D0 (en) * 2006-04-25 2006-06-07 Astex Therapeutics Ltd Pharmaceutical Compounds
ES2878130T3 (es) * 2006-04-25 2021-11-18 Astex Therapeutics Ltd Derivados de purina y deazapurina como compuestos farmacéuticos
WO2008012635A2 (fr) * 2006-07-26 2008-01-31 Pfizer Products Inc. Dérivés d'amines utiles en tant qu'agents anticancéreux
US20080161320A1 (en) * 2006-09-11 2008-07-03 Xiong Cai Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
KR20090077914A (ko) * 2006-09-11 2009-07-16 쿠리스 인코퍼레이션 항증식제로서의 다작용성 소분자
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
WO2008075007A1 (fr) * 2006-12-21 2008-06-26 Cancer Research Technology Limited Composé bicyclohétéroarylés substitué par morpholino et leur utilisation en tant qu'agents anti-cancer
EP2121692B1 (fr) 2006-12-22 2013-04-10 Incyte Corporation Hétérocycles substitués servant d'inhibiteurs de janus kinases
WO2008084861A1 (fr) 2007-01-12 2008-07-17 Astellas Pharma Inc. Composé de pyridine condensée
CA2682646A1 (fr) * 2007-04-02 2008-10-09 Palau Pharma, S.A. Derives de pyrrolopyrimidine
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
LT3070090T (lt) 2007-06-13 2019-06-25 Incyte Holdings Corporation Janus kinazės inhibitoriaus (r)-3-(4-(7h-pirol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropannitrilo druskų panaudojimas
GB0713602D0 (en) * 2007-07-12 2007-08-22 Syngenta Participations Ag Chemical compounds
ES2562218T3 (es) * 2007-07-27 2016-03-03 Janssen Pharmaceutica, N.V. Pirrolopirimidinas útiles para el tratamiento de enfermedades proliferativas
CN101772502A (zh) 2007-08-08 2010-07-07 莱西肯医药有限公司 作为激酶抑制剂用于治疗癌和炎症的(7H-吡咯并[2,3-d]嘧啶-4-基)哌嗪类化合物
WO2009030871A1 (fr) * 2007-09-07 2009-03-12 Vernalis R & D Ltd Dérivés de pyrrolopyrimidine présentant une activité inhibitrice d'hsp90
ME01999B (me) 2007-10-11 2015-05-20 Astrazeneca Ab Derivati pirolo[2,3-d]pirimidina kao inhibitori protein kinaze b
US8309718B2 (en) 2007-11-16 2012-11-13 Incyte Corporation 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors
KR101240882B1 (ko) 2008-03-11 2013-03-11 인사이트 코포레이션 Ｊａｋ 억제제로서의 아제티딘 및 시클로부탄 유도체
JP5575110B2 (ja) * 2008-04-21 2014-08-20 レクシコン ファーマシューティカルズ インコーポレイテッド Ｌｉｍｋ２阻害剤、それらを含む組成物、及びそれらの使用の方法
WO2009132202A2 (fr) 2008-04-24 2009-10-29 Incyte Corporation Composés macrocycliques et leur utilisation à titre d'inhibiteurs de kinase
CA2733359C (fr) 2008-08-20 2014-08-05 Pfizer Inc. Composes pyrrolo[2,3-d]pyrimidines
US8385364B2 (en) * 2008-09-24 2013-02-26 Nec Laboratories America, Inc. Distributed message-passing based resource allocation in wireless systems
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
JOP20190230A1 (ar) * 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
DE102009005193A1 (de) * 2009-01-20 2010-07-22 Merck Patent Gmbh Neue heterocyclische Verbindungen als MetAP-2 Inhibitoren
US8765727B2 (en) 2009-01-23 2014-07-01 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
JP2012517448A (ja) 2009-02-11 2012-08-02 リアクション バイオロジー コープ． 選択的キナーゼ阻害剤
EP3026052A1 (fr) 2009-04-20 2016-06-01 Auspex Pharmaceuticals, Inc. Preparation des inhibiteurs pipéridiniques deuteriés de la janus kinase3
DK2432472T3 (da) 2009-05-22 2019-11-18 Incyte Holdings Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer
EA025520B1 (ru) * 2009-05-22 2017-01-30 Инсайт Холдингс Корпорейшн N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
EP2451813B1 (fr) 2009-07-08 2014-10-01 Leo Pharma A/S Composés hétérocycliques en tant qu inhibiteurs du récepteur jak et de la protéine tyrosine kinase
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
TW201111385A (en) * 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
JP5699149B2 (ja) 2009-09-04 2015-04-08 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬
CA2773131C (fr) * 2009-09-04 2015-07-14 The Regents Of The University Of Michigan Compositions et methodes de traitement de la leucemie
CA2777114C (fr) 2009-10-09 2018-10-23 Incyte Corporation Derives hydroxy, ceto et glucuronides de 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3- cyclopentylpropanenitrile
AP2012006192A0 (en) 2009-10-15 2012-04-30 Pfizer PyrroloÄ2,3-DÜ pyrimidine compounds.
US9074143B2 (en) * 2009-12-11 2015-07-07 Uop Llc Process for producing hydrocarbon fuel
JP5739446B2 (ja) 2009-12-18 2015-06-24 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
CA2788071A1 (fr) 2010-02-05 2011-08-11 Pfizer Inc. Composes d'uree a base de pyrrolo[2,3-d]pyrimidine a titre d'inhibiteurs de jak
JP5858434B2 (ja) * 2010-02-18 2016-02-10 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｎｕｓキナーゼ阻害薬としてのシクロブタンおよびメチルシクロブタン誘導体
SMT201800137T1 (it) 2010-03-10 2018-07-17 Incyte Holdings Corp Derivati di piperidin-4-il azetidina come inibitori di jak1
KR101921466B1 (ko) 2010-05-21 2018-11-26 인사이트 홀딩스 코포레이션 Ｊａｋ 저해제에 대한 국소 제형
TW201204732A (en) * 2010-07-09 2012-02-01 Leo Pharma As Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
AU2011291185C1 (en) 2010-08-20 2015-04-16 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
WO2012022045A1 (fr) * 2010-08-20 2012-02-23 Hutchison Medipharma Limited Composés pyrrolopyrimidiniques et leurs utilisations
CN102372717B (zh) * 2010-08-20 2014-06-18 和记黄埔医药（上海）有限公司 吡咯并嘧啶类化合物及其用途
TWI401258B (zh) * 2010-09-08 2013-07-11 Hutchison Medipharma Ltd 吡咯並嘧啶類化合物及其用途
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
CA2818542A1 (fr) 2010-11-19 2012-05-24 Incyte Corporation Derives pyrrolopyridine et pyrrolopyrimidine a substitution cyclobutyle utilises comme inhibiteurs des jak
JP5927201B2 (ja) 2010-12-16 2016-06-01 カルチャン リミテッド Ａｓｋ１阻害ピロロピリミジン誘導体
WO2012088682A1 (fr) * 2010-12-29 2012-07-05 Shanghai Fochon Pharmaceutical Co Ltd. Dérivés de la 2-(3-aminopipéridin-1-yle)-[1,2,4] triazolo [1,5-c] pyrimidine-5,7 (3h,6h)-dione en tant qu'inhibiteurs de la dipeptidylpeptidase iv(dpp-iv)
US9233964B2 (en) 2011-01-07 2016-01-12 Leo Pharma A/S Sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use therof
DE102011008352A1 (de) * 2011-01-12 2012-07-12 Merck Patent Gmbh 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate
CA2826295C (fr) 2011-02-04 2020-10-20 Duquesne University Of The Holy Spirit Inhibiteurs pyrimidines bicycliques et tricycliques de tyrosine kinase ayant une activite antitubuline, et methodes de traitement d'un patient
ES2547916T3 (es) 2011-02-18 2015-10-09 Novartis Pharma Ag Terapia de combinación de inhibidores de mTOR/JAK
JP6277121B2 (ja) 2011-03-22 2018-02-07 アドヴィナス・セラピューティックス・リミテッド 置換された縮合三環式化合物、その組成物および医学的応用
EA027506B1 (ru) 2011-04-01 2017-08-31 Астразенека Аб Способ лечения рака молочной железы
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
AU2012275638A1 (en) * 2011-06-29 2013-11-14 Merck Sharp & Dohme Corp. Process for preparing chiral dipeptidyl peptidase-IV inhibitors
BR112014000314A2 (pt) * 2011-07-08 2017-01-10 Novartis Ag derivados de pirrolo pirimidina
WO2013023119A1 (fr) 2011-08-10 2013-02-14 Novartis Pharma Ag Polythérapie par jak p13k/mtor
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CA2856722C (fr) 2011-11-30 2022-11-22 Emory University Inhibiteurs de jak antiviraux utiles dans le traitement ou la prevention d'infections retrovirales et autres infections virales
SMT201900708T1 (it) 2011-11-30 2020-01-14 Astrazeneca Ab Trattamento di combinazione di un cancro
EP2788000B1 (fr) * 2011-12-06 2018-05-30 Merck Sharp & Dohme Corp. Pyrrolopyrimidines en tant qu'inhibiteurs de kinase janus
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
AP3902A (en) * 2012-06-29 2016-11-17 Pfizer Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors
ES2889757T3 (es) * 2012-09-06 2022-01-13 Plexxikon Inc Compuestos y procedimientos para la modulación de quinasas e indicaciones para estos
EP2897962A1 (fr) 2012-09-21 2015-07-29 Advinus Therapeutics Limited Composés tricycliques condensés substitués, compositions et applications médicales correspondantes
JP6139690B2 (ja) * 2012-10-26 2017-05-31 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルートンチロシンキナーゼの阻害剤
CN102936251A (zh) * 2012-11-05 2013-02-20 上海毕得医药科技有限公司 一种吡咯并[2,3-d]嘧啶衍生物的制备方法
BR112015010663B1 (pt) 2012-11-15 2022-12-06 Incyte Holdings Corporation Formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
EP2958921B1 (fr) 2013-02-22 2017-09-20 Pfizer Inc Dérivés de pyrrolo-[2,3-d]pyrimidine en tant qu'inhibiteurs des janus kinases (jak)
CA3091179C (fr) 2013-03-06 2023-01-17 Incyte Holdings Corporation Procedes et intermediaires pour la generation d'un inhibiteur de jak
WO2014139388A1 (fr) * 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
TWI822248B (zh) 2013-08-07 2023-11-11 美商英塞特控股公司 Jak1抑制劑之持續釋放劑型
HUE035264T2 (hu) * 2013-12-05 2018-05-02 Pfizer Pirrolo[2,3-d]pirimidinil-, pirrolo[2,3-b]pirazinil- és pirrolo[2,3-d]-piridinil- akrilamidok
JP6487921B2 (ja) 2013-12-17 2019-03-20 ファイザー・インク ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
EP3180344B1 (fr) 2014-08-12 2019-09-18 Pfizer Inc Dérivés de pyrrolo[2,3-d]pyrimidine utiles pour inhiber la janus kinase
US10246464B2 (en) 2014-09-09 2019-04-02 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
CN105524067A (zh) * 2014-09-28 2016-04-27 江苏柯菲平医药股份有限公司 4-取代吡咯并[2,3-d]嘧啶化合物及其用途
ES2928757T3 (es) 2015-05-01 2022-11-22 Pfizer Acrilamidas de pirrolo[2,3-b]pirazinilo y epóxidos de las mismas como inhibidores de la Janus Quinasa
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
EP3302057A4 (fr) 2015-06-04 2018-11-21 Kura Oncology, Inc. Méthodes et compositions d'inhibition de l'interaction de la ménine avec les protéines mll
DK3330271T3 (da) * 2015-07-31 2022-11-14 Taiho Pharmaceutical Co Ltd PYRROLO[2,3-d]PYRIMIDINFORBINDELSE ELLER SALT DERAF
KR101771219B1 (ko) * 2015-08-21 2017-09-05 양지화학 주식회사 야누스 키나제 1 선택적 억제제 및 그 의약 용도
MX2018003215A (es) 2015-09-14 2018-06-08 Pfizer Derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftirid ina novedosos como inhibidores de lrrk2.
WO2017091681A1 (fr) 2015-11-24 2017-06-01 Aclaris Therapeutics, Inc. Inhibiteurs de kinase sélectifs
CN107098908B (zh) 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
AU2017235462B2 (en) 2016-03-16 2021-07-01 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-MLL and methods of use
US10781218B2 (en) 2016-03-16 2020-09-22 Kura Oncology, Inc. Substituted inhibitors of menin-MLL and methods of use
CN107513067A (zh) 2016-06-16 2017-12-26 北京赛林泰医药技术有限公司 含有取代环戊基的吡咯并嘧啶化合物
CN107513069A (zh) * 2016-06-16 2017-12-26 正大天晴药业集团股份有限公司 手性吡咯并嘧啶化合物的制备方法
WO2018017153A1 (fr) 2016-07-21 2018-01-25 Biogen Ma Inc. Formes de succinate et compositions d'inhibiteurs de tyrosine kinase de bruton
US10316038B2 (en) 2017-01-25 2019-06-11 Aclaris Therapeutics, Inc. Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer
JP7101176B2 (ja) * 2017-02-03 2022-07-14 レオ ファーマ アクティーゼルスカブ 新規ＪＡＫキナーゼ阻害剤としての５－（７Ｈ－ピロロ［２，３－ｄ］ピリミジン－４－イル）－５－アザスピロ［２．５］オクタン－８－カルボン酸誘導体
WO2018175746A1 (fr) 2017-03-24 2018-09-27 Kura Oncology, Inc. Méthodes de traitement d'hémopathies malignes et du sarcome d'ewing
CN108794480A (zh) * 2017-04-28 2018-11-13 天津药物研究院有限公司 吡咯并嘧啶类化合物、其制备方法和用途
WO2018226976A1 (fr) 2017-06-08 2018-12-13 Kura Oncology, Inc. Procédés et compositions d'inhibition de l'interaction de la ménine avec les protéines mll
US11649251B2 (en) 2017-09-20 2023-05-16 Kura Oncology, Inc. Substituted inhibitors of menin-MLL and methods of use
WO2019090143A1 (fr) 2017-11-03 2019-05-09 Aclaris Therapeutics, Inc. Analogues de pyrrolo[2,3-b]pyrimidine-5-carboxylate de pyrazolyle et leurs procédés de préparation
BR112020008850A2 (pt) 2017-11-03 2020-10-20 Aclaris Therapeutics, Inc. composto, composição farmacêutica e método para tratar uma doença mediada por jak1 e jak3
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US10899736B2 (en) 2018-01-30 2021-01-26 Incyte Corporation Processes and intermediates for making a JAK inhibitor
AU2019245420B2 (en) 2018-03-30 2024-10-10 Incyte Corporation Treatment of hidradenitis suppurativa using JAK inhibitors
EP3833350A4 (fr) 2018-08-10 2022-05-18 Aclaris Therapeutics, Inc. Inhibiteurs de pyrrolopyrimidine itk
GB201818750D0 (en) * 2018-11-16 2019-01-02 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
CN109394768B (zh) * 2018-12-10 2019-08-23 牡丹江医学院 一种治疗湿疹的药物及其制备方法
NL2022471B1 (en) 2019-01-29 2020-08-18 Vationpharma B V Solid state forms of oclacitinib
EP3946606B1 (fr) * 2019-03-27 2025-01-01 Insilico Medicine IP Limited Inhibiteurs de jak bicycliques et leurs utilisations
AU2020265828A1 (en) 2019-05-02 2021-09-09 Aclaris Therapeutics, Inc. Substituted pyrrolopyridines as JAK inhibitors
JOP20210298A1 (ar) 2019-05-14 2023-01-30 Provention Bio Inc طرق وتركيبات للوقاية من مرض السكري من النوع الأول
CN115038443A (zh) 2019-11-22 2022-09-09 因西特公司 包含alk2抑制剂和jak2抑制剂的组合疗法
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
JP2023530109A (ja) 2020-06-11 2023-07-13 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
US20250051337A1 (en) * 2021-09-28 2025-02-13 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of serine/threonine protein kinase stk3 or stk4 and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3037980A (en) 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
GB915303A (en) 1958-03-13 1963-01-09 Wellcome Found Pyrrolo[2,3-d]pyrimidine derivatives and the manufacture thereof
NO169490C (no) 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
JP2983254B2 (ja) 1989-06-14 1999-11-29 武田薬品工業株式会社 ピロロ〔２，３―ｄ〕ピリミジン誘導体の製造法およびその中間体
PT633886E (pt) * 1992-04-03 2001-03-30 Upjohn Co Aminas biciclicas-heterociclicas farmaceuticamente activas
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
US5389509A (en) 1993-10-04 1995-02-14 Eastman Kodak Company Ultrathin high chloride tabular grain emulsions
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
DK0682027T3 (da) 1994-05-03 1998-05-04 Ciba Geigy Ag Pyrrolopyrimidinderivater med antiproliferativ virkning
JP3290666B2 (ja) * 1995-06-07 2002-06-10 ファイザー・インコーポレーテッド 複素環式の縮合環ピリミジン誘導体
AU6478396A (en) 1995-07-05 1997-02-05 E.I. Du Pont De Nemours And Company Fungicidal pyrimidinones
EA001428B1 (ru) * 1995-07-06 2001-02-26 Новартис Аг Пирролопиримидины и фармацевтические композиции, включающие эти соединения
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
EA000072B1 (ru) 1995-11-14 1998-06-25 Фармация Энд Апджон С.П.А. Бициклическое конденсированное пиримидиновое соединение и его применение в качестве терапевтического агента
EP0888349B1 (fr) * 1996-01-23 2002-05-22 Novartis AG Pyrrolopyrimidines et leurs procedes de preparation
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
GB9604361D0 (en) * 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
WO1997032879A1 (fr) 1996-03-06 1997-09-12 Novartis Ag 7-ALKYLE-PYRROLO[2,3-d]PYRIMIDINES
WO1997049706A1 (fr) 1996-06-25 1997-12-31 Novartis Ag 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES SUBSTITUES ET UTILISATION DE CES COMPOSES
PE91098A1 (es) 1996-07-13 1999-01-15 Glaxo Group Ltd DERIVADOS DE PIRIDO[3,4-d]PIRIMIDINA
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
PT938486E (pt) 1996-08-23 2008-03-27 Novartis Ag Pirrolopirimidinas substituídas e processos para a sua preparação
AU4718997A (en) * 1996-11-27 1998-06-22 Pfizer Inc. Fused bicyclic pyrimidine derivatives
CA2271157A1 (fr) 1997-02-05 1998-08-06 Warner-Lambert Company Pyrido[2,3d]pyrimidines et 4-aminopyrimidines en tant qu'inhibiteurs de la proliferation cellulaire
US6187552B1 (en) 1997-03-24 2001-02-13 Pharmacia & Upjohn Company Method for identifying inhibitors of JAK2/cytokine receptor binding
WO1999051599A1 (fr) 1998-04-02 1999-10-14 Neurogen Corporation Derives aminoalkyle substitues de pyrrolo[2,3-b]pyridine et pyrrolo[2,3-d]pyrimidine: modulateurs de recepteurs de crf1
AU4317399A (en) 1998-05-28 1999-12-13 Parker Hughes Institute Quinazolines for treating brain tumor
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
EP1087970B1 (fr) 1998-06-19 2004-04-28 Pfizer Products Inc. COMPOSES DE PYRROLO 2,3d]PYRIMIDINE
JP2004504259A (ja) 1998-06-30 2004-02-12 パーカー　ヒューズ　インスティテュート Ｊａｋ−３インヒビターを用いたｃ−ｊｕｎ発現の阻害方法
AU5682799A (en) 1998-08-21 2000-03-14 Parker Hughes Institute Quinazoline derivatives
BR9913887A (pt) 1998-09-18 2001-10-23 Basf Ag Composto, e, métodos de inibir a atividade de proteìna quinase, de tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase e de diminuir a fertilidade em um paciente
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
US6664252B2 (en) * 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
SK287188B6 (sk) 1999-12-10 2010-02-08 Pfizer Products Inc. Pyrolo [2,3-d]pyrimidínová zlúčenina, jej použitie a farmaceutická kompozícia alebo kombinácia s jej obsahom
PT1294724E (pt) 2000-06-26 2006-07-31 Pfizer Prod Inc Compostos pirrolo (2,3-d ) pirimidina como agentes imunosupressivos
US6680324B2 (en) * 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) * 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
GT200200234A (es) 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
KR20040006555A (ko) 2002-07-12 2004-01-24 삼성전자주식회사 액정 표시 장치

Also Published As

Publication number Publication date
ID27595A (id) 2001-04-12
EA006034B1 (ru) 2005-08-25
IS2461B (is) 2008-11-15
EA010377B1 (ru) 2008-08-29
GT199900091A (es) 2000-12-09
TR200003720T2 (tr) 2001-03-21
SA99200285B1 (ar) 2006-05-23
HK1036800A1 (en) 2002-01-18
PA8474101A1 (es) 2000-09-29
NO318786B1 (no) 2005-05-09
IS2395B (is) 2008-08-15
EP1087971A1 (fr) 2001-04-04
AU758427B2 (en) 2003-03-20
HRP20000886B1 (en) 2008-07-31
YU79700A (sh) 2003-04-30
AP9901583A0 (en) 1999-06-30
IS5722A (is) 2000-11-21
HRP20000886A2 (en) 2001-10-31
EA200500614A1 (ru) 2005-12-29
EA200001188A1 (ru) 2001-06-25
KR20010053005A (ko) 2001-06-25
CZ20004726A3 (cs) 2002-03-13
HUP0103472A3 (en) 2002-12-28
UA63013C2 (en) 2004-01-15
CN1125070C (zh) 2003-10-22
ES2223172T3 (es) 2005-02-16
DE69918552D1 (de) 2004-08-12
SK286685B6 (sk) 2009-03-05
US20040058922A1 (en) 2004-03-25
CO5320601A1 (es) 2003-09-30
SI1087971T1 (en) 2004-10-31
PL198639B1 (pl) 2008-07-31
JP2002518394A (ja) 2002-06-25
DK1087971T3 (da) 2004-10-11
IS5721A (is) 2000-11-21
EG23758A (en) 2007-08-08
NZ508034A (en) 2003-11-28
IL139598A0 (en) 2002-02-10
WO1999065909A1 (fr) 1999-12-23
IL139598A (en) 2008-08-07
PT1087971E (pt) 2004-10-29
OA11571A (en) 2004-07-01
HUP0103472A2 (hu) 2002-02-28
TW542834B (en) 2003-07-21
AP1157A (en) 2003-06-30
MY125802A (en) 2006-08-30
SK18992000A3 (sk) 2002-08-06
TNSN99125A1 (fr) 2005-11-10
CN1305479A (zh) 2001-07-25
CA2335186A1 (fr) 1999-12-23
DE69918552T2 (de) 2004-11-04
KR100452054B1 (ko) 2004-10-08
NO20050201L (no) 2001-02-15
US7569569B2 (en) 2009-08-04
PL345118A1 (en) 2001-12-03
CA2335186C (fr) 2005-03-29
HN1999000083A (es) 2001-05-22
ZA994003B (en) 2000-12-18
BR9912171A (pt) 2001-04-10
GEP20084336B (fr) 2008-03-25
US6635762B1 (en) 2003-10-21
BG65063B1 (bg) 2007-01-31
AU4054599A (en) 2000-01-05
JP3497823B2 (ja) 2004-02-16
PE20000639A1 (es) 2000-07-26
NO20006454L (no) 2001-02-15
ATE270673T1 (de) 2004-07-15
EP1087971B1 (fr) 2004-07-07
AR016498A1 (es) 2001-07-04
NO20006454D0 (no) 2000-12-18
BG105122A (en) 2001-10-31

Similar Documents

Publication Publication Date Title
MA26653A1 (fr) Pyrrolo [2,3- d] pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26654A1 (fr) Pyrrolopyrimidines nouvelles procede pour leur preparation et compositions pharmaceutiques les contenant
FR2780057B1 (fr) Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26687A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26622A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26468A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26630A1 (fr) 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26479A1 (fr) Derives de nicotinamide, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26472A1 (fr) Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA24529A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions les contenant .
MA26559A1 (fr) Derives de d-proline, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation
MA26433A1 (fr) Derives de pyridylpyrrole, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26465A1 (fr) Derives de quinoleine et derives de quinazoline nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26686A1 (fr) Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26424A1 (fr) Derives de 6-phenylpyridyl-2-amine, procede pour leur preparation et compositions pharmaceutiques les contenant.
DZ2890A1 (fr) 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26415A1 (fr) Composes heterocycliques, procede pour la preparation et compositions pharmaceutiques les contenant
MA26471A1 (fr) Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26669A1 (fr) 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26680A1 (fr) Derives de quinoleine-2-one a substituant alcynyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26614A1 (fr) Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26499A1 (fr) Derives de tetrazole, procede pour leur preparation et compositions pharmaceutiques les contenant .
FR2729951B1 (fr) Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
MA26508A1 (fr) Formulations pharmaceutiques contenant du variconazole, et procede pour leur preparation.
MA26505A1 (fr) Derives de 6-o-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant